Who is sponsoring NCT02709096?

NCT02709096 is sponsored by BioPharmX, Inc..

What condition does NCT02709096 study?

NCT02709096 studies Acne Vulgaris.

What drugs are being tested in NCT02709096?

Interventions: BPX-01, 1% Topical Gel, BPX-01 Vehicle Gel.

What is the status of NCT02709096?

NCT02709096 is currently COMPLETED.

Last reviewed 2017-08-16 · How we verify

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

NCT02709096 Phase 2 COMPLETED Results posted

This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.

Details

Lead sponsor	BioPharmX, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	33
Start date	2016-04
Completion	2016-06

Conditions

Acne Vulgaris

Interventions

BPX-01, 1% Topical Gel
BPX-01 Vehicle Gel

Primary outcomes

Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes — Cultures will be evaluated at Baseline, Week 1, Week 2, Week 4 and Week 6. Values reported at week 4 compared to baseline.
P. Acnes cultures will be collected using the modified Kligman Method at each study visit. After plating, the samples will be cultured for 7 days and then evaluated.

Countries

United States